Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001337 · ClinicalTrials.gov registry record · Phase 2
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 348
- Enrollment target
NCT00001337: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00001337 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 348 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001337, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 348 participants
- Enrollment target
Study Summary
5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. Etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH): Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; with Granulocyte Colony-Stimulating Factor (Amgen), Granulocyte colony-stimulating factor (G-CSF), NSC-614629.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Vincristine
- DRUG Prednisone
- BIOLOGICAL Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 1993-05-08 |
| Est. Completion | 2024-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001337
The ClinicalTrials.gov registry entry for NCT00001337 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00001337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001337 about?
NCT00001337 is a clinical study titled "Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma". 5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. Etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin)(EPOCH): Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574;...
What is the current status of trial NCT00001337?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 348 participants. The study started on 1993-05-08. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT00001337?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Vincristine (DRUG), Prednisone (DRUG), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001337?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.